Kansas City Southern (NYSE: KSU ) will release its quarterly report on Friday, with the stock having risen to levels it hasn't seen since it spun off its interest in Janus Capital back in 2000. But as much as healthy conditions in the railroad industry have helped Kansas City Southern earnings, there's another potential elephant in the room that's also contributing to investors' interest in the stock.
Kansas City Southern is a relative baby in the railroad industry, with several of its larger peers having five to 10 times as much revenue as the regional carrier. But the railroad's size gives it some important strategic advantages over its peers as well, including the prospects for larger competitors to use a takeover bid to expand their own rail networks. Let's take an early look at what's been happening with Kansas City Southern over the past quarter and what we're likely to see in its quarterly report.
Stats on Kansas City Southern
Analyst EPS Estimate
Top 5 Recreation Stocks To Own Right Now: Christopher & Banks Corporation (CBK)
Christopher & Banks Corporation, through its subsidiaries, operates retail stores that provide women�s apparel and accessories in the United States. The company designs, sources, and sells apparel catering to customers generally ranging in age from 45 to 60. Its stores offer knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrications, and dresses in various sizes, as well as jewelry and accessories. As of March 13, 2013, the company operated 605 stores in 44 states, including 381 Christopher & Banks stores, 158 C.J. Banks stores, 41 dual stores, and 25 outlet stores. It also operates e-Commerce Web sites christopherandbanks.com and cjbanks.com. The company was formerly known as Braun�s Fashions Corporation and changed its name to Christopher & Banks Corporation in July 2000. Christopher & Banks Corporation was founded in 1956 and is headquartered in Plymouth, Minnesota.
Advisors' Opinion:- [By Laura Brodbeck]
Wednesday
Earnings Expected From: Christopher & Banks Corporation (NYSE: CBK), Brown Forman Corporation (NYSE: BFB), Express, Inc. (NYSE: EXPR), Avago Technologies (NASDAQ: AVGO) Economic Releases Expected: US nonfarm employment change, US trade balance, Canadian trade balance, US new home sales, US ISM non-manufacturing PMIThursday
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Christopher & Banks (NYSE: CBK ) , whose recent revenue and earnings are plotted below.
Hot Railroad Stocks For 2014: Arena Pharmaceuticals Inc.(ARNA)
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company?s clinical development programs include lorcaserin that has completed two pivotal Phase III clinical trials for the treatment of weight management, including weight loss and maintenance of weight loss; and APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. Its preclinical development programs include APD334, for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. The company also researches and develops cannabinoid, receptor agonists for the treatment of osteoarthritis and pain; and GPR119 agonists for the treatment of type 2 diabetes. Its other development programs, which had completed Phase I clinical trial include APD597 for th e treatment of type II diabetes; APD916 for the treatment of narcolepsy and cataplexy; and APD791 for the treatment of arterial thrombosis. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of obesity-fighting biotech Arena Pharmaceuticals (NASDAQ: ARNA ) shed as much as 11% today following its first-quarter earnings results and the company announcing the withdrawal of its European Union marketing application for Belviq.
- [By Brian Orelli]
Observe the peaks in July 2012 after the FDA approved VIVUS'� (NASDAQ: VVUS ) and Arena Pharmaceuticals' (NASDAQ: ARNA ) obesity drugs. VIVUS launched Qsymia a few months later to lackluster sales. Arena's Belviq was just launched earlier this month after waiting for the DEA to sign off on the drug's scheduling. While Arena sits a little lower than its post-approval high, it still has a ways to fall if the drug also fails to meet investors' expectations.
Hot Railroad Stocks For 2014: IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories, Inc., incorporated in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through three segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller segments that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
The Company sells a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its primary products and services are point-of-care veterinary diagnostic products, consisting of instruments and consumables and rapid assays; veterinary reference laboratory diagnostic and consulting services used by veterinarians; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; practice management systems and services and digital radiography systems used by veterinarians; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.
Companion Animal Group
The Company markets a range of in-clinic laboratory analyzers for use in providing reference laboratory quality diagnostic results in companion animal veterinary practices, which it refers ! to as the IDEXX VetLab suite of analyzers. The Company sells two chemistry analyzers, the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, that are used by veterinarians to measure levels of certain enzymes and other substances in blood or urine for monitoring health status and assistance in diagnosing physiologic conditions. Both instruments use consumables manufactured for IDEXX by Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, based on Ortho�� dry slide technology (Catalyst Dx slides, VetTest slides or slides). In addition, the Catalyst Dx analyzer also uses dry slide electrolyte consumables manufactured by IDEXX at OPTI Medical Systems, one of its wholly owned subsidiaries. Blood tests commonly run on these analyzers include glucose, alkaline phosphatase, alanine aminotransferase (ALT), albumin, creatinine, blood urea nitrogen (BUN), and total protein. Tests are sold individually and in prepackaged panels. Both analyzers also run a urine test called urine protein:creatinine ratio, which assists in the detection of early renal disease.
The Catalyst Dx analyzer is the Company�� chemistry analyzer. The Catalyst Dx analyzer allows a veterinarian to run multiple patient samples simultaneously; to run different sample types, including whole blood, plasma, serum and urine; to perform 28 different chemistry and electrolyte tests; and to automatically calculate other parameters and ratios important to blood chemistry analysis. Its VetLyte Electrolyte Analyzer measures three electrolytes-sodium, potassium and chloride-to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Its VetStat Electrolyte and Blood Gas Analyzer measures electrolytes, blood gases, glucose and ionized calcium, and calculates other parameters, such as base excess and anion gap. These measurements aid veterinarians in diagnosing various disease states, evaluating fluid therapy choices and measuring respiratory function. The VetStat analyzer ru! ns single! -use disposable cassettes that contain various configurations of analytes. The VetStat analyzer and its cassettes are manufactured by OPTI Medical Systems.
The Company sells three hematology analyzers that assess the cellular components of blood, including red blood cells, white blood cells and platelets (also called a complete blood count (CBC)). These analyzers include the ProCyte Dx Hematology Analyzer, which uses laser-flow cytometry, optical fluorescence and laminar-flow impedance in its analysis; the LaserCyte Hematology Analyzer, which uses laser-flow cytometry technology in its analysis, and the IDEXX VetAutoread Hematology Analyzer. It also sells the Coag Dx Analyzer, which permits the detection and diagnosis of blood clotting disorders. The ProCyte Dx analyzer provides validated results for five species (canine, feline, equine, bovine and ferret) for up to 24 different blood parameters, providing a more complete picture of each patient�� health.
The SNAPshot Dx analyzer provides quantitative measurements of total thyroxine (T4), cortisol and bile acids to assist in the evaluation of thyroid, adrenal and liver function. The SNAPshot Dx analyzer also reads, interprets and records the results of many IDEXX rapid assay SNAP tests, including its canine SNAP 4Dx test, feline SNAP FIV/FeLV Combo test, canine SNAP cPL test, feline SNAP fPL test, SNAP Feline Triple test and canine SNAP Heartworm RT test. The IDEXX VetLab UA Analyzer provides chemical urinalysis and is validated specifically for veterinary use. The IDEXX VetLab Station (IVLS) connects and integrates the diagnostic information from all the IDEXX VetLab equipment and thus provides reference laboratory information management system capability. It sells the IVLS as an integral component of the Catalyst Dx, LaserCyte and ProCyte Dx analyzers and also as a standalone hardware platform.
The IVLS includes a user interface to input patient information, connect with a practice management system and send i! nformatio! n to run the individual analyzers. IVLS also generates one integrated patient report incorporating all of the lab work generated by the IDEXX VetLab suite; stores, retrieves and analyzes historical patient diagnostics data, including SNAP test results; and sends and receives information from practice management systems, including the IDEXX Cornerstone system, as well as a variety of third-party systems. It sells a range of single-use, handheld test kits under the SNAP name. In addition to its single-use tests, it sells a range of microwell-based test kits under the PetChek name for canine heartworm, FIV and FeLV.
The Company offers commercial reference laboratory diagnostic and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, South Africa, China and South Korea and to bioresearch customers in the United States and Europe. The Company provides specialized veterinary consultation, telemedicine and advisory services, including radiology, cardiology, internal medicine and ultrasound consulting. It develops, markets and sells practice management systems, including hardware and software, and services that run certain functions of veterinary clinics, including managing patient electronic health records, scheduling (including boarding and grooming), reminders, billing and inventory management.
The Company markets and sells two digital radiography systems for use in the small animal veterinary hospital: the IDEXX-DR 1417 and the IDEXX I-Vision CR. Its digital radiography systems use IDEXX-PACS and IDEXX EquiView PACS picture archiving and communication system (PACS) software for the viewing, manipulation, management, storage and retrieval of the digital images generated by the digital capture plate. In September 2011, the Company launched IDEXX I-Vision Mobile, an application that allows veterinarians with the IDEXX-DR 1417 and IDEXX I-Vision CR systems, as well as its digital radiography systems, to request, view and send images using an iPa! d or an A! ndroid mobile tablet. This application integrates with its IDEXX-PACS software.
Water
The Company offers a range of products used in the detection and quantification of various microbiological parameters in water. Its principal products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as indicators of microbial contamination in water. These products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Its water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.
Livestock and Poultry Diagnostics
The Company sells diagnostic tests and related instrumentation that are used to detect a range of diseases and to monitor health status in livestock and poultry. Its livestock and poultry diagnostic products are purchased by government and private laboratories that provide testing services to cattle, swine and poultry veterinarians and producers. Its principal products include tests for Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS) and Bovine Spongiform Encephalopathy (BSE or mad cow disease). BVDV is a common and contagious viral infection that suppresses the immune system, making the animal susceptible to a host of other infections, impacting beef and dairy production yields as a result. PRRS is a contagious virus causing reproductive problems and respiratory diseases. BSE is a fatal neurodegenerative disease in cattle that causes a spongy degeneration in the brain and spinal cord.
Other
The principal products in the Company�! � Dairy ! business are its SNAP tests used to detect antibiotic drug-residue in milk. Its primary product line for detecting antibiotic residue in milk is SNAP Beta-Lactam, which detects penicillin, amoxicillin, ceftiofur and cephaphirin residues, followed by SNAPduo Beta-Tetra, which detects certain tetracycline antibiotic residues in addition to those detected by the SNAP Beta Lactam test kits. It also sells SNAP tests for the detection of certain other contaminants in milk, such as chemical melamine and Alfatoxin M1.
The Company sells OPTI point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, lactate, BUN and ionized calcium, and to calculate other parameters, such as base excess and anion gap. These analyzers are used primarily in emergency rooms, operating rooms, cardiac monitoring areas and other locations where time-critical diagnostic testing is performed within the hospital setting. The OPTI CCA and OPTI Touch Electrolyte and Blood Gas Analyzers run single-use disposable cassettes that contain various configurations of analytes; the OPTI R Analyzer runs reusable cassettes in various analyte configurations; and the OPTI LION Stat Electrolyte Analyzer runs single-use electrolyte cassettes. OPTI Medical Systems also manufactures its VetStat analyzer and provides the electrolyte module and dry slide reagents that make up the electrolyte testing functionality of the Catalyst Dx analyzer.
The Company competes with VCA Antech, Inc., Abaxis, Inc., Butler, Radiometer A/S, Siemens Medical Solutions Diagnostics, Instrumentation Laboratory, Abbott Diagnostics and Roche Diagnostics.
Advisors' Opinion:- [By Sean Williams]
On the diagnostic side, there isn't a company better equipped to help veterinarians diagnose bone and organ disease, or help veterinarians improve the efficiency of their software, than IDEXX Laboratories (NASDAQ: IDXX ) . From small diagnostic analyzers to high-tech digital imagery and even consultation calls, IDEXX does it all for owners and veterinarians. The best part is that the company's companion diagnostics make up the bulk (83%) of its revenue, so the chance of IDEXX seeing a slowdown in demand appears pretty minimal.
Hot Railroad Stocks For 2014: QR Energy LP(QRE)
QR Energy, LP, through its subsidiary, QRE Operating, LLC, engages in the acquisition, production, and development of onshore crude oil and natural gas properties in the United States. As of March 31, 2011, its properties consisted of working interests in 2,140 gross producing wells located in Alabama, Arkansas, Kansas, Louisiana, New Mexico, Oklahoma, and Texas. QRE GP, LLC operates as the general partner of the company. QR Energy, LP was founded in 2006 and is based in Houston, Texas.
Advisors' Opinion:- [By Robert Rapier]
While I still think LRE units are undervalued, BreitBurn Energy Partners probably presents a more compelling case at present.
QR Energy (NYSE: QRE) reported a solid third quarter, with earnings before interest, taxation, depreciation and amortization (EBITDA) up 13 percent to $69 million. Production was up 5 percent despite a disruption at some of it operations.
Distributable cash flow for the quarter was up 26 percent to $35 million, or $0.54 per unit, adequately covering its current distribution of $0.4875. (The partnership will convert to monthly distributions in 2014.) Based on Friday’s close, this translates into an annualized yield of 11.8 percent. Given that QRE’s solid performance came despite temporary production issues, it looks like a decent bet in the upstream MLP space for 2014.
- [By Lee Jackson]
QR Energy L.P. (NYSE: QRE) is an energy total return home run for investors. This MLP after a recent acquisition is now one of the largest producers (2,300 barrels per day) in the historic East Texas oil field. Raymond James has a $19 target, the consensus is at $20. Investors are paid a huge 11.7% distribution. MLP distributions may include return of principal.
Hot Railroad Stocks For 2014: Optimer Pharmaceuticals Inc.(OPTR)
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing hospital specialty products worldwide. It develops products that treat gastrointestinal infections and related diseases. The company provides two late-stage anti-infective product candidates, including Fidaxomicin, a narrow spectrum antibiotic for the treatment of Clostridium difficile-infection, which completed two Phase 3 trials; and Pruvel, a prodrug in the fluoroquinolone class of antibiotics, has completed two Phase 3 trials for the treatment of infectious diarrhea, including traveler?s diarrhea. It also develops product candidates using its proprietary technology Optimer One-Pot Synthesis, a computer-aided technology that enables the rapid synthesis of various proprietary molecules. In addition, the company?s other pipeline product candidates consist of CEM-101 (OP-1068), a macrolide and ketolide antibiotic, which is in Phase 2 trials for the treatment of upper and lower respiratory tract infections; and OPT-822/821, a novel carbohydrate-based cancer immunotherapy, is in Phase 2/3 trials for the treatment of metastatic breast cancer. It has collaborative agreements with Astellas Pharma Europe Ltd.; Par Pharmaceuticals, Inc.; Nippon Shinyaku, Co., Ltd.; Cempra Pharmaceuticals, Inc.; Memorial Sloan-Kettering Cancer Center; and The Scripps Research Institute. Optimer Pharmaceuticals, Inc. was founded in 1998 and is based in San Diego, California.
Advisors' Opinion:- [By Keith Speights]
"Bidness" is good (part 2)
Obagi isn't the only company for which "bidness" is good. Antibiotic maker�Optimer Pharmaceuticals (NASDAQ: OPTR ) shares soared 22% this week on talk of interest by multiple potential buyers.
No comments:
Post a Comment